Novel anti-metastatic treatments

News

Cancer affects one in three individuals and is the leading cause of death below the age of 75 in most Western countries. Over the last decades, enormous efforts have been focused on improving diagnostics and therapeutics for cancer. However, besides the great achievements in childhood leukaemia and testicular cancer, the overall mortality rates remain virtually constant.

Wnt-5a negative and positive tumour cells

The primary tumour is rarely the cause of death of cancer patients. In fact, in the vast majority of cases, cancer-associated mortality is the result of cancer cell dissemination to other organs, i.e. metastasis. The inherent problem with most current therapeutic approaches is their failure to target the dissemination process whereby tumour cells travel from the site of the primary tumour to surrounding or distant tissues.

The focus and aim of WntResearch is to develop novel anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process.

New Members of the Board

Peter Buhl Jensen, Chairman of the Board. Co-founder and CEO until 2010 of Topo Targets A/S, Denmark.

Bert Junno, Member of the Board. CEO Ideon Science Park, Lund, Sweden.

Carl Borrebaeck, Member of the Board. Professor and deputy vice-chancellor at Lund University. Co-founder of BioInvent International AB and Alligator Science AB.

Lars Larsson, Member of the Board. Medical Licensing Director at AstraZeneca R&D, Sweden.